Acute myeloid leukemia developing in patients with autoimmune diseases

Myelodysplastisches Syndrom, akute Leukämie und Stammzelltransplantation

“…Die Inzidenz scheint bei Patienten mit bestimmten Autoimmunerkrankungen leicht erhöht zu sein. Dies gilt laut Registerdaten für die rheumatoide Arthritis und den systemischen Lupus erythematodes [11,12]. Lediglich für Cyclophosphamid konnte bislang ein eindeutiger medikamentö-ser Einfluss gezeigt werden.…”

Development of Acute Promyelocytic Leukemia in a Patient With Gouty Arthritis on Long Term Colchicine

“…We know that gouty arthritis is associated with increased risk of cancer but the data shown this association with mostly solid cancers [2]. Also the data from comprehensive population based study shown association between autoimmune disease and acute myeloid leukemia (subtype mostly APL), there is no data about gouty arthritis [3]. APL is a particular subtype of AML often characterized by particular cytogenetic abnormalities [1,3].…”

“…It is known that autoimmune and chronic inflammatory conditions can develop into malignant, leukemia or lymphoproliferative diseases [1][2][3]. Ozdogu et al [1] were the first to describe an association between colchicine use and development of acute promyelocytic leukemia (APL).…”

“…Colchicine is often used to treat gout, gouty arthritis, familial Mediterranean fever, and Behcet's syndrome [1,3]. The questions are: does an association exist between development of APL and inflammatory disease or the association is linked to chronicle use of colchicine?…”

“…Also the data from comprehensive population based study shown association between autoimmune disease and acute myeloid leukemia (subtype mostly APL), there is no data about gouty arthritis [3]. APL is a particular subtype of AML often characterized by particular cytogenetic abnormalities [1,3]. The actions of colchicine at the cellular level are not directly associated with DNA modification, but genotoxic and mutagenic effects of colchicine on many cell types have been reported [1,5].…”